Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Pediatr Blood Cancer. 2012 Aug;59(2):333-4. doi: 10.1002/pbc.23327. Epub 2012 Jan 3.
T-cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50-60% of the T-cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second-generation tyrosine kinase inhibitor, directly targets the BCR-ABL gene. We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.
T 细胞急性淋巴细胞白血病（T-cell acute lymphoblastic leukemia，T-ALL）占儿童 ALL 病例的 15%，与预后较差相关。细胞遗传学研究显示，50-60%的 T-ALL 患者存在染色体异常；约 8%的病例存在 ABL1 融合。达沙替尼是一种第二代酪氨酸激酶抑制剂，可直接靶向 BCR-ABL 基因。我们描述了一例 T-ALL 患儿，该患儿 ABL1 基因扩增，仅在添加达沙替尼到常规化疗后才获得缓解。
